Why the study?
Does a separate stent endograft improve angiographic and clinical success compared to a conventional thoracic stent-graft in patients with type B aortic dissection?
Does a separate stent endograft improve angiographic and clinical success compared to a conventional thoracic stent-graft in patients with type B aortic dissection?
A percutaneous separate stent endograft demonstrated comparable angiographic and clinical success to conventional stent-grafts for type B aortic dissection, with potentially fewer access site complications.
Answers are grounded in this paper and cite their sources.
Comparable success rates do not support adoption; leaves open need for randomized trials in type B aortic dissection.
PURPOSE: To compare the immediate and midterm outcomes of aortic dissection repair with a separate stent endograft (SSE) versus a conventionally constructed thoracic stent-graft. METHODS: The records of 35 patients treated for type B aortic dissection from September 1997 to April 2003 were reviewed. Seventeen patients (12 men; mean age 58.8+/-11.6 years) underwent endovascular repair with a separate stent endograft (SSE), a custom-made device with a reduced profile suitable for percutaneous introduction through a 12-F sheath. Eighteen patients (10 men; mean age 56.1+/-12.8 years) underwent treatment with a conventional custom-made stent-graft. RESULTS: Angiographic success was achieved in 13/17 (76.5%) of the SSE-treated patients and 12/18 (66.7%) for the conventional device group (p=0.521). Clinical success (complete obliteration/thrombosis of the false lumen) was achieved in 12/17 (70.6%) and 11/18 (61.1%), respectively (p=0.555). There were 2 cases of stent-graft movement during deployment and 2 access site complications in the conventional stent-graft group, whereas the SSE patients had no complications. Except for 2 conventional stent-graft patients who were lost to follow-up, all patients are alive at a mean 19.5+/-11.6 months for the SSE group and 34.2+/-21.5 months for the conventional stent-graft patients. CONCLUSIONS: The separate stent endograft can be deployed percutaneously without the need for blood pressure reduction, achieving accurate deployment without migration. In this small clinical experience, patients treated with the SSE had no access site complications and demonstrated midterm results comparable to the conventional stent-graft cohort, suggesting the possible usefulness of this device for the treatment of thoracic aortic dissection.
No takes yet. Share an insight, caveat, or question.
Park et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: